查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1636768

2030 年筛检检测市场预测：按检测类型、性别、最终用户和地区进行的全球分析

Breast Cancer Screening Tests Market Forecasts to 2030 - Global Analysis By Test Type (Blood Tests, Imaging Test, Genetic Test, Biopsy, Tomosynthesis and Other Test Types), Gender, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球筛检筛检市场预计在 2024 年达到 22.9 亿美元，到 2030 年预计将达到 40.1 亿美元，预测期内的复合年增长率为 9.8%。

筛检测试是一种用于在未表现出症状的个体中检测乳癌早期迹象的医疗程序。主要的筛检方法包括乳房X光摄影、超音波、核磁共振成像和3D乳房X光摄影（断层合成）。这些检查旨在识别乳房组织的异常生长或变化，以便儘早诊断和治疗。定期筛检可以在早期、更易治疗的阶段发现肿瘤，有助于提高存活率，尤其是对于乳癌高风险族群。

根据欧洲乳癌联盟 2023 年的预测，乳癌将成为 2023 年欧洲最常见的癌症，新增病例约 38 万例，主要发生在女性身上。

提高早期检测意识

提高人们对早期检测的认识对于筛检测试市场的扩大至关重要。随着越来越多的人意识到早期发现癌症的重要性，对筛检服务的需求急剧增加。医疗保健宣传活动、媒体关注和教育活动正在强调早期检测的救命益处。由于这些认识，筛检计画的参与人数增加，尤其是在高风险族群。许多筛检方法，包括乳房X光摄影、核磁共振成像和超音波，都被广泛使用，因为透过定期筛检进行早期发现可以改善治疗效果和存活率。

辐射暴露问题

对辐射暴露的担忧是乳癌筛检技术市场发展的一大障碍，尤其是当乳房 X乳房X光摄影等标准程序使用低剂量的 X 光时。虽然乳房X光摄影中使用的辐射量较低且对大多数女性来说是安全的，但长期暴露会对健康造成风险，包括增加罹患癌症的风险。对于某些女性，尤其是年轻女性或有家族病史的女性来说，这些担忧可能会阻碍她们进行频繁的筛检。目前正在研究替代性的无辐射筛检方法，例如 MRI 和超音波，以降低这些风险并确保有效的早期检测。

提高对遗传风险因子的认识

人们对遗传风险（尤其是与 BRCA1 和 BRCA2 基因突变相关的遗传风险）认知的提高，使得更多人选择早期筛检和基因检测。因此，建议女性，特别是有乳癌家族病史的女性，从小就定期进行筛检。遗传咨询结合MRI和乳房X光摄影等筛检测试，可以识别高风险患者并促进早期发现和主动监测。随着人们认识的提高，对更好的筛检技术和基因检测的需求也在增加。

缺乏熟练的医疗保健专业人员

合格医护人员，尤其是放射科医师和技术人员的短缺，是筛检筛检市场发展的一大障碍。需要高素质的专家来准确地解释乳房X光摄影等筛检资料，而缺乏专家可能会导致诊断延迟和筛检效果降低。缺乏训练有素的工作人员限制了许多地区，特别是农村和贫困社区获得及时检测的机会，对早期检测工作产生了负面影响。这种短缺进一步给医疗保健系统带来了压力，凸显了资助教育计画和创建人工智慧诊断技术以协助医疗保健工作者的必要性。

COVID-19 的影响

COVID-19 疫情严重扰乱了乳癌筛检市场。这是因为许多医疗机构已暂停常规筛检，以优先治疗 COVID-19。这可能会导致早期检测延迟并影响患者的治疗结果。此外，对被锁在门外或接触病毒的恐惧也使人们不愿寻求筛检服务。然而，随着医疗保健系统的适应，包括实施安全措施、增加远端医疗的使用以及注重恢復延迟的筛检以进行早期诊断，经济正在逐步復苏。

预测期内，影像检查领域预计将成为最大的市场

受 3D乳房X光摄影、MRI 和超音波等诊断技术的进步推动，影像检查领域估计是最大的领域。这些影像检查可以提高准确性，更早发现肿瘤，并区分良性和恶性肿瘤。此外，乳癌发生率的不断上升以及早期检测意识的增强也推动了影像检查的普及。技术创新、影像解析度的提高以及人工智慧的融合正在进一步提高影像在乳癌诊断中的有效性。

预测期内，诊断实验室部门预计将以最高复合年增长率成长

由于使用乳房X光摄影、超音波和 MRI 等先进技术提供专业诊断服务，预计诊断实验室部门将在预测期内实现最高的复合年增长率。对准确和早期乳癌检测的需求不断增长，推动了诊断实验室的发展。此外，医疗基础设施的改善和乳癌预防意识的增强也导致了患者数量的增加。实验室提供及时准确的诊断结果的能力对于乳癌的早期发现和治疗越来越重要。

比最大的地区

由于医疗保健意识的增强、乳癌发病率的上升以及可支配收入的增加，预计亚太地区将在预测期内占据最大的市场占有率。快速的都市化和不断改善的医疗保健基础设施使得筛检服务更加容易获得。在日本、中国和印度等国家，政府采取措施和筛选计画促进早期发现。此外，人们对女性健康意识的不断提高和诊断技术的进步进一步推动了该全部区域乳癌筛检测试的采用。

复合年增长率最高的地区：

受高标准医疗保健、强有力的政府支持和先进的医疗技术等因素推动，预计北美地区在预测期内将实现最高的复合年增长率。广泛的筛检项目，包括乳房X光摄影和核磁共振成像，鼓励早期发现和预防护理。人们对乳癌的认识不断提高，加上医疗保险覆盖范围的扩大，正在鼓励人们定期进行乳癌筛检。此外，人口老化、高可支配收入以及获得尖端诊断工具的机会也促进了北美市场的成长。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业进行基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球筛检测试市场（依测试类型）

  • 血液检查
  • 影像检查
    • 乳房X光检查
    • 磁振造影（MRI）
    • 正子断层扫描
    • 超音波
  • 基因检测
    • 萤光原位杂合反应
    • HER基因检测
  • 切片检查
  • 断层合成
  • 其他测试类型

6. 全球筛检筛检市场（依性别）

  • 男性
  • 女士

7. 全球筛检检测市场（以最终用户划分）

  • 诊断实验室
  • 医院
  • 专科门诊
  • 癌症研究所
  • 研究实验室
  • 其他最终用户

8. 全球乳癌筛检检测市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章 主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司概况

  • GE Healthcare
  • Hologic, Inc.
  • Siemens Healthineers
  • Philips Healthcare
  • Canon Medical Systems Corporation
  • Koninklijke Philips NV
  • Fujifilm Holdings Corporation
  • IQM Diagnostics
  • Medtronic PLC
  • 3M Health Care
  • Samsung Medison Co., Ltd.
  • Carestream Health, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Volpara Health Technologies
  • Medimaps Group
  • Dilon Technologies, Inc.
  • LumaVision
  • Aurora Imaging Technology, Inc.
Product Code: SMRC28410

According to Stratistics MRC, the Global Breast Cancer Screening Tests Market is accounted for $2.29 billion in 2024 and is expected to reach $4.01 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Breast cancer screening tests are medical procedures used to detect early signs of breast cancer in individuals who show no symptoms. The primary screening methods include mammography, ultrasound, MRI, and 3D mammography (tomosynthesis). These tests aim to identify abnormal growths or changes in breast tissue, allowing for early diagnosis and treatment. Regular screening helps improve survival rates by detecting tumours at an earlier, more treatable stage, especially in individuals at higher risk for breast cancer.

According to the European Breast Cancer Coalition 2023, breast cancer was the most commonly diagnosed cancer in Europe in 2023, with around 380,000 new cases, primarily among women.

Market Dynamics:

Driver:

Increasing awareness of early detection

Growing awareness of early detection is essential to the market expansion for breast cancer screening tests. Demand for screening services has increased dramatically as more individuals realize how important it is to detect cancer in its early stages. Health organizations' campaigning, media attention, and educational efforts have highlighted the life-saving advantages of early identification. Participation in screening programs has increased as a result of this knowledge, particularly among high-risk groups. Numerous screening techniques, including mammography, MRI, and ultrasound, are being used by a wide range of demographics due to the fact that early identification through routine screening improves treatment results and survival rates.

Restraint:

Radiation exposure concerns

Concerns about radiation exposure present a major obstacle to the market for breast cancer screening technologies, especially when using low-dose X-rays in standard procedures like mammography. Even while the radiation used in mammograms is considered to be low and safe for the majority of women, prolonged exposure might cause health hazards, such as an elevated risk of cancer. Particularly for younger women or those with a family history of cancer, these worries may discourage some people from getting frequent checkups. Alternative, non-radiative screening techniques like MRI and ultrasound are now being investigated in an effort to lower these hazards and guarantee efficient early identification.

Opportunity:

Rising awareness of genetic risk factors

Growing awareness of genetic risks, especially those associated with mutations in the BRCA1 and BRCA2 genes, has led to an increase in the number of people choosing early screening and genetic testing. Women are encouraged to get regular screenings at a younger age because of this awareness, particularly those who have a family history of breast cancer. When paired with screening procedures like MRIs and mammograms, genetic counseling assists in identifying high-risk patients, facilitating early detection and proactive monitoring. The need for better screening techniques and genetic testing is increasing along with awareness.

Threat:

Shortage of skilled healthcare professionals

The lack of qualified medical personnel, especially radiologists and technicians, is a major obstacle in the market for breast cancer screening testing. It takes highly qualified specialists to accurately interpret screening data, such mammograms, and their absence can cause delays in diagnosis and decreased screening efficacy. The lack of trained staff restricts access to timely tests in many areas, particularly in rural or underprivileged areas, which has a detrimental effect on early detection initiatives. Healthcare systems are further burdened by this scarcity, underscoring the necessity of funding educational initiatives and the creation of AI-powered diagnostic technologies to assist medical practitioners.

Covid-19 Impact

The COVID-19 pandemic significantly disrupted the breast cancer screening tests market, as many healthcare facilities temporarily suspended routine screenings to prioritize COVID-19 care. This led to delays in early detection, potentially affecting patient outcomes. Additionally, lockdowns and fear of exposure to the virus discouraged individuals from seeking screening services. However, as healthcare systems adapt, there has been a gradual recovery with the implementation of safety measures, increased use of telemedicine, and a focus on resuming delayed screenings for early diagnosis.

The imaging test segment is expected to be the largest during the forecast period

The imaging test segment is estimated to be the largest, driven by advancements in diagnostic technologies, such as 3D mammography, MRI, and ultrasound. These imaging tests provide higher accuracy, early detection of tumours, and better differentiation between benign and malignant growths. Additionally, the increasing prevalence of breast cancer, along with rising awareness of early detection, fuels the adoption of imaging tests. Technological innovations, improved image resolution, and integration of artificial intelligence further enhance the effectiveness of imaging in breast cancer diagnosis.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostic laboratories segment is anticipated to witness the highest CAGR during the forecast period, as they provide specialized diagnostic services using advanced technologies like mammography, ultrasound, and MRI. The increasing demand for accurate and early breast cancer detection fuels growth in diagnostic labs. Additionally, improved healthcare infrastructure and rising awareness of breast cancer prevention contribute to higher patient volumes. Laboratories' ability to offer timely and precise diagnostic results further enhances their importance in the early detection and treatment of breast cancer.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to growing healthcare awareness, increasing breast cancer prevalence, and rising disposable incomes. Rapid urbanization and improvements in healthcare infrastructure are making screening services more accessible. Government initiatives and screening programs in countries like Japan, China, and India are promoting early detection. Additionally, a rising focus on women's health, coupled with advancements in diagnostic technologies, further boosts the adoption of breast cancer screening tests across the region.

Region with highest CAGR:

During the forecast period, the North America region is anticipated to register the highest CAGR, fueled by factors such as high healthcare standards, strong government support, and advanced medical technologies. The widespread availability of screening programs, including mammography and MRI, encourages early detection and preventive care. Rising awareness about breast cancer, coupled with increased health insurance coverage, promotes regular screenings. Additionally, the aging population, high disposable incomes, and access to cutting-edge diagnostic tools further contribute to the market's growth in North America.

Key players in the market

Some of the key players profiled in the Breast Cancer Screening Tests Market include GE Healthcare, Hologic, Inc., Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Koninklijke Philips N.V., Fujifilm Holdings Corporation, IQM Diagnostics, Medtronic PLC, 3M Health Care, Samsung Medison Co., Ltd., Carestream Health, Inc., Inovio Pharmaceuticals, Inc., Volpara Health Technologies, Medimaps Group, Dilon Technologies, Inc., LumaVision, and Aurora Imaging Technology, Inc.

Key Developments:

In March 2024, Philips strengthens strategic partnership with Sim&Cure to expand innovation in neurovascular therapy. Philips announced the expansion of its strategic partnership with Sim&Cure, a leading provider of advanced digital solutions for neurovascular therapy. The partnership between the two companies started 5 years ago.

In May 2024, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, announced it has signed an agreement to acquire 100% of the shares of Sonio SAS, a fetal ultrasound AI software company.

In March 2024, GE Healthcare Wipro, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, today announced an investment of over INR8000 Crores in manufacturing output & local R&D over next 5 years.

Test Types Covered:

  • Blood Tests
  • Imaging Test
  • Genetic Test
  • Biopsy
  • Tomosynthesis
  • Other Test Types

Genders Covered:

  • Male
  • Female

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Specialty Clinics
  • Cancer Institutes
  • Research Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Screening Tests Market, By Test Type

  • 5.1 Introduction
  • 5.2 Blood Tests
  • 5.3 Imaging Test
    • 5.3.1 Mammography
    • 5.3.2 Magnetic Resonance Imaging (MRI)
    • 5.3.3 PET Scan
    • 5.3.4 Ultrasound
  • 5.4 Genetic Test
    • 5.4.1 Fluorescence In Situ Hybridization
    • 5.4.2 HER gene test
  • 5.5 Biopsy
  • 5.6 Tomosynthesis
  • 5.7 Other Test Types

6 Global Breast Cancer Screening Tests Market, By Gender

  • 6.1 Introduction
  • 6.2 Male
  • 6.3 Female

7 Global Breast Cancer Screening Tests Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals
  • 7.4 Specialty Clinics
  • 7.5 Cancer Institutes
  • 7.6 Research Laboratories
  • 7.7 Other End Users

8 Global Breast Cancer Screening Tests Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 GE Healthcare
  • 10.2 Hologic, Inc.
  • 10.3 Siemens Healthineers
  • 10.4 Philips Healthcare
  • 10.5 Canon Medical Systems Corporation
  • 10.6 Koninklijke Philips N.V.
  • 10.7 Fujifilm Holdings Corporation
  • 10.8 IQM Diagnostics
  • 10.9 Medtronic PLC
  • 10.10 3M Health Care
  • 10.11 Samsung Medison Co., Ltd.
  • 10.12 Carestream Health, Inc.
  • 10.13 Inovio Pharmaceuticals, Inc.
  • 10.14 Volpara Health Technologies
  • 10.15 Medimaps Group
  • 10.16 Dilon Technologies, Inc.
  • 10.17 LumaVision
  • 10.18 Aurora Imaging Technology, Inc.

List of Tables

  • Table 1 Global Breast Cancer Screening Tests Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 3 Global Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 4 Global Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 5 Global Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 6 Global Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 7 Global Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 8 Global Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 9 Global Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 10 Global Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 11 Global Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 12 Global Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 13 Global Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 14 Global Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 15 Global Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 16 Global Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 17 Global Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 18 Global Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 19 Global Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 20 Global Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 21 Global Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 22 Global Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 23 Global Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 24 Global Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 25 North America Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 26 North America Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 27 North America Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 28 North America Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 29 North America Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 30 North America Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 31 North America Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 32 North America Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 33 North America Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 34 North America Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 35 North America Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 36 North America Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 37 North America Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 38 North America Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 39 North America Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 40 North America Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 41 North America Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 42 North America Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 43 North America Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 44 North America Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 45 North America Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 46 North America Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 47 North America Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 48 North America Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 49 Europe Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 50 Europe Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 51 Europe Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 52 Europe Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 53 Europe Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 54 Europe Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 55 Europe Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 56 Europe Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 57 Europe Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 58 Europe Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 59 Europe Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 60 Europe Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 61 Europe Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 62 Europe Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 63 Europe Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 64 Europe Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 65 Europe Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 66 Europe Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 67 Europe Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 68 Europe Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 69 Europe Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 70 Europe Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 71 Europe Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 72 Europe Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 73 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 74 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 75 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 76 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 77 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 78 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 79 Asia Pacific Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 80 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 81 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 82 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 83 Asia Pacific Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 84 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 85 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 86 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 87 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 88 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 89 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 90 Asia Pacific Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 91 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 92 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 93 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 94 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 95 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 96 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 97 South America Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 98 South America Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 99 South America Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 100 South America Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 101 South America Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 102 South America Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 103 South America Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 104 South America Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 105 South America Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 106 South America Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 107 South America Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 108 South America Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 109 South America Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 110 South America Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 111 South America Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 112 South America Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 113 South America Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 114 South America Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 115 South America Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 116 South America Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 117 South America Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 118 South America Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 119 South America Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 120 South America Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 121 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
  • Table 122 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 123 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 124 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
  • Table 125 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
  • Table 126 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 127 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
  • Table 128 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
  • Table 129 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
  • Table 130 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
  • Table 131 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
  • Table 132 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 133 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
  • Table 134 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
  • Table 135 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
  • Table 136 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
  • Table 137 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
  • Table 138 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
  • Table 139 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 140 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 141 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 142 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
  • Table 143 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
  • Table 144 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)